Merck/Schering Zetia Has 50% Combo Use; Statin Of Choice Is Lipitor
Executive Summary
Prescriptions for Merck/Schering-Plough's Zetia during the drug's first six weeks on the market have been split equally between monotherapy and combination use with other cholesterol-reduction products
You may also be interested in...
Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says
Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels
Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says
Merck/Schering's Zetia/Zocor fixed-dose combination will be positioned as a first-line, cholesterol-lowering therapy, while Zetiawill be reserved primarily for the niche population of patients who are not at their target cholesterol levels
Merck/Schering Zetia Early Use Is In High-Risk Patients; New Rx Share At 5%
Schering-Plough is seeing most of the early use of Zetia in either high-risk or statin-intolerant patients, Global Pharmaceuticals President Carrie Cox told investors during a quarterly earnings call Oct. 22